Westat Awarded Contract to Continue Supporting the PATH Study
ROCKVILLE, Md., Feb. 21, 2024 /PRNewswire/ -- The National Institutes of Health's (NIH's) National Institute on Drug Abuse (NIDA) and the U.S. Food and Drug Administration's (FDA's) Center for Tobacco Products (CTP) have announced the award of a third contract to Westat to continue to support the Population Assessment of Tobacco and Health (PATH) Study. Westat has supported the study since its inception in 2011.
- Westat is committed to continuing the trusted partnership with NIH/NIDA and FDA/CTP on the Population Assessment of Tobacco and Health (PATH) Study to understand tobacco use patterns and impacts on public health.
- Westat has supported the study since its inception in 2011.
- The PATH Study is a uniquely large, long-term study of tobacco use and health in the United States.
- "Our work will build on the knowledge we have gained during the past 12 years of supporting the PATH Study and a foundation of over 35 years of tobacco research," notes Charles Carusi, PhD , a Westat Vice President and the project director for the PATH Study.